Natera, Inc. (NASDAQ:NTRA) Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC increased its position in Natera, Inc. (NASDAQ:NTRA) by 7.4% during the third quarter, HoldingsChannel.com reports. The fund owned 2,090,480 shares of the medical research company’s stock after acquiring an additional 143,825 shares during the quarter. Geode Capital Management LLC’s holdings in Natera were worth $265,747,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Itau Unibanco Holding S.A. purchased a new stake in Natera during the second quarter worth $28,000. Quarry LP raised its stake in shares of Natera by 148.4% during the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after buying an additional 190 shares during the last quarter. Covestor Ltd boosted its position in shares of Natera by 34.3% in the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after buying an additional 95 shares in the last quarter. GAMMA Investing LLC grew its stake in Natera by 32.7% in the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after acquiring an additional 106 shares during the last quarter. Finally, True Wealth Design LLC purchased a new position in Natera during the 3rd quarter valued at about $57,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Trading Up 0.1 %

Shares of NTRA opened at $166.55 on Friday. The stock’s fifty day simple moving average is $144.02 and its 200 day simple moving average is $124.56. Natera, Inc. has a twelve month low of $57.22 and a twelve month high of $175.63. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $21.99 billion, a P/E ratio of -94.63 and a beta of 1.63.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.31. The business had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company’s revenue was up 63.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.95) EPS. On average, equities research analysts forecast that Natera, Inc. will post -1.61 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Roelof Botha sold 87,473 shares of the company’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $169.12, for a total transaction of $14,793,433.76. Following the completion of the sale, the director now directly owns 1,224,787 shares of the company’s stock, valued at approximately $207,135,977.44. This represents a 6.67 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Steven Leonard Chapman sold 5,024 shares of the firm’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $128.48, for a total value of $645,483.52. Following the completion of the transaction, the chief executive officer now directly owns 195,686 shares in the company, valued at $25,141,737.28. This trade represents a 2.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 137,987 shares of company stock worth $21,895,591 over the last ninety days. 7.60% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms have recently commented on NTRA. Craig Hallum increased their price target on shares of Natera from $121.00 to $157.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Piper Sandler increased their target price on Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a report on Monday, November 18th. Canaccord Genuity Group boosted their price target on Natera from $150.00 to $165.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Leerink Partners increased their price objective on Natera from $140.00 to $150.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Finally, Sanford C. Bernstein boosted their target price on shares of Natera from $125.00 to $135.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. One analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the stock. According to MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and an average target price of $152.67.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.